

ECONOMIC IMPACT OVER THE PAST 4 YEARS ASSOCIATED WITH BIOLOGICAL THERAPY OPTIMISATION IN RHEUMATIC DISEASES PATIENTS

Cavada-Carranza I¹, Alonso-Zazo FJ¹, Martínez-Núñez ME¹, Vázquez-Sánchez R¹, Sánchez-Rubio-Ferrández J¹, Aragón-Díez A², Rodríguez-Heredia JM², Molina-García T¹

¹Pharmacy Department Hospital Universitario de Getafe, ²Rheumatology Department Hospital Universitario de Getafe

OBJECTIVES

To evaluate biologic-therapies (BT) optimization patterns in patients with rheumatic diseases (RD) and associated economic savings

MATERIALS and METHODS

Observational and retrospective study

All patients with RD treated with BT from January 2014 to June 2018 were included

Rheumatoid arthritis (RA)

Spondyloarthropathies (SA)

Psoriatic arthritis (PSA)

BT optimization

Dose reduction

Prolonging the dosing interval

Patients \geq 6 months in **CLINICAL REMISSION** or **MINIMAL CLINICAL ACTIVITY**

DAS28 $<$ 2,6 (RA and PSA)
BASDAI $<$ 2 (SA)

DAS28 $<$ 3,2 (RA and PSA)
BASDAI $<$ 4 (SA)

Variables were described as frequencies and means:

Diagnosis Subcutaneous BT Dose regimens Total treatment duration Time on BT optimization (TO) Treatment costs

Abatacept
Adalimumab
Certolizumab
Etanercept

Golimumab
Secukinumab
Tocilizumab
Ustekinumab

Cost saving / patient \rightarrow Comparing optimization treatment costs vs conventional treatment

Cost saving globally \rightarrow Comparing real cost vs theoretical conventional doses cost

RESULTS



N= 448 \rightarrow BT treatments= 579

Biologic-therapies optimization

From all patients \rightarrow 47% was in BT optimization


Adalimumab

60%

Etanercept



The most common BT used in RD treatment

BT optimization/diagnosis



Time on BT optimization

Mean TO duration = 2,2 years



Cost saving

BT optimization allowed a 50% saving per patient against the use of conventional therapy

Reduction of the total cost

€3.000.000

Total economic savings

21%

CONCLUSIONS

- ✓ Therapeutic decision-making based on validated disease activity scales has allowed the BT optimization in approximately 50% of patients with RD
- ✓ Patients remain clinically controlled after BT optimization for a mean time of 2 years
- ✓ The BT optimization allows to reduce costs maintaining the effectiveness

